Diversified Trust Co Grows Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Diversified Trust Co grew its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IARTFree Report) by 37.3% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 22,846 shares of the life sciences company’s stock after acquiring an additional 6,208 shares during the quarter. Diversified Trust Co’s holdings in Integra LifeSciences were worth $810,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Signaturefd LLC increased its holdings in shares of Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after acquiring an additional 415 shares during the last quarter. Hexagon Capital Partners LLC increased its holdings in shares of Integra LifeSciences by 123.3% in the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after acquiring an additional 370 shares during the last quarter. Gladius Capital Management LP purchased a new position in shares of Integra LifeSciences in the 3rd quarter valued at about $47,000. Mitsubishi UFJ Asset Management UK Ltd. purchased a new position in shares of Integra LifeSciences in the 4th quarter valued at about $131,000. Finally, Northwest Investment Counselors LLC acquired a new stake in shares of Integra LifeSciences in the 1st quarter valued at about $143,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on IART shares. Oppenheimer cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 7th. Truist Financial decreased their target price on Integra LifeSciences from $37.00 to $25.00 and set a “hold” rating for the company in a research report on Tuesday, May 7th. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Bank of America decreased their target price on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a research report on Tuesday, May 7th. Finally, JMP Securities decreased their target price on Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $33.88.

Check Out Our Latest Analysis on IART

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, Chairman Stuart Essig bought 52,641 shares of the business’s stock in a transaction dated Thursday, May 23rd. The stock was acquired at an average cost of $28.49 per share, with a total value of $1,499,742.09. Following the purchase, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 3.10% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $29.19 on Wednesday. The company has a market cap of $2.30 billion, a price-to-earnings ratio of 58.38, a price-to-earnings-growth ratio of 1.05 and a beta of 1.11. The stock has a 50 day simple moving average of $28.61 and a 200-day simple moving average of $35.42. Integra LifeSciences Holdings Co. has a 12-month low of $22.36 and a 12-month high of $46.75. The company has a current ratio of 4.68, a quick ratio of 3.35 and a debt-to-equity ratio of 1.15.

Integra LifeSciences (NASDAQ:IARTGet Free Report) last issued its earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.55. The business had revenue of $368.90 million during the quarter, compared to the consensus estimate of $361.96 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.74 EPS. On average, equities analysts forecast that Integra LifeSciences Holdings Co. will post 3.03 EPS for the current year.

About Integra LifeSciences

(Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

See Also

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.